Hamad, Jimer A.

HRN: 21-75-40  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/21/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
12/21/2022
12/27/2022
IV
120mg
Q24Hrs
PCAP-D
Waiting Final Action 

Indication:  Empiric    Type of Infection:  PneumoniaBloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: